-$8.57
-$3.58
bear -$8.57
base -$5.97
bull -$3.58
margin of safety $3.00
market price* $21.95
Business condition attached to the margin of safety
Two consecutive fiscal years of positive owner earnings (operating cash flow excluding working-capital swings, after stock-based compensation and maintenance capital spending) of at least about $10 million (~$0.40 per share), achieved without new equity issuance or incremental borrowing to fund operations.
OrthoPediatrics, based in Warsaw, Indiana, designs and sells implants, instruments and specialized braces made for children with orthopedic conditions, and runs a group of pediatric orthotic and prosthetic clinics. Implants and instruments are made by contract manufacturers. In 2025 revenue was $236.3 million, up 15%: trauma and deformity products (Cannulated Screws, PNP Femur, PediPlate, external fixation, Pega) were 70% and scoliosis products (RESPONSE 5.5/6.0, 7D Technology, ApiFix Mid-C) were 28%. The company says nearly all of the growth came from selling more units, not from raising prices. About 79% of revenue ($186.4 million) came from the United States and the rest from international markets. Gross margin was 73%. The problem is cash. Revenue grew more than sixfold between 2016 and 2025, yet the cash the business produces for its owners has been negative in every one of those ten years. We measure that as operating cash flow, with swings in inventory and other working capital taken out, minus stock-based pay and minus the equipment spending needed to keep the current business running. On that basis the business lost between $9 million and $30 million a year. For 2021 to 2025, when the company already looked much as it does today, the middle figure is a loss of about $19.5 million a year, roughly 81 cents a share. We use that as the starting level. 2025 looked better on the surface: operating cash flow was negative $4.9 million against negative $27.0 million in 2024. Most of that gain came from building less inventory and paying suppliers more slowly, which are timing effects, so we take them out. Stock-based pay reached $17.8 million in 2025, up from $6.7 million in 2022. We count it as a real cost because it dilutes shareholders. Our conclusion does not depend on the equipment estimate. With no equipment charge at all, 2025 was still a loss of $11.8 million. Only if both stock pay and equipment spending were ignored would 2025 show a positive figure, of about $6 million. The loss has not narrowed as the company has grown. Net loss for the first half of 2026 was $17.9 million, against $17.8 million a year earlier, even though revenue rose 14% to $129.9 million. Growing sales have not yet turned into profit, so none of our cases credits them. Sales growth only helps owners if costs stop rising just as fast, and the record does not yet show that. Base case: the loss stays near $19.5 million a year for ten years. Most growth spending (inventory build, acquisitions, and the growth share of spending on new instrument sets) is already left out of that figure, and what remains is the cost of running the business. Year 1 assumes no change from this level, which is roughly the 2025 loss of $19.7 million. We see nothing specific in the filings that would carry earnings beyond ten years, so the story ends there. That is worth about -$5.97 a share today. Bear case: the loss returns to the 2024 level of about $26 million. On top of that comes about $2 million a year of extra interest if the company draws the additional $20 million term loan it arranged in March 2026 (available through June 2027, at a rate of at least 9.75%). That is worth about -$8.57 a share. The company carries a $50 million term loan due August 2029, at SOFR plus 6.5% with a 3.25% floor, and $50 million of 4.75% convertible notes due February 2030 that convert at about $40.98 a share. Cash and short-term investments were $45.9 million at June 30, 2026. At the current rate of cash use, both debts will probably need refinancing or new equity. The company also keeps writing down acquisitions: in 2025 it took $4.6 million of trademark write-downs on ApiFix, MedTech, Orthex and Telos, wrote off $1.9 million of goodwill, and exited the Telos consulting business. It spent $20.2 million buying Boston O&P in 2024 and $15.5 million on other acquisitions and clinics in 2025. Bull case: cost cutting from the 2024 restructuring (folding ApiFix into the scoliosis line, staff reductions, a smaller site in Israel) and lower equipment spending bring the loss back to about $11.7 million a year, its best level in the past five years (2021). That is worth about -$3.58 a share. We did not credit a move to profit, because the business has never produced one. All three figures are negative. This is not because debt outweighs the company's assets. Stockholders' equity was $343.6 million on the books at June 30, 2026, and inventory alone was $137.6 million. The figures are negative because, on its record, the business needs cash from its owners each year to keep running. The values show what that funding would cost today if the pattern continues for another decade. Any value in the shares rests on profits the company has not yet shown it can make. What would prove this wrong: two consecutive years in which the business produces cash after stock-based pay and equipment spending, without new borrowing or share sales. If the business reached about $10 million a year, or about 40 cents a share, the shares would be worth roughly $7 on that level alone. The margin-of-safety price of $3.00 applies only after that happens. The large discount reflects the $100 million of debt due in 2029 and 2030.